| Basics |
Sangamo Therapeutics, Inc.
Sangamo Therapeutics Inc is a clinical stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
|
| IPO Date: |
April 6, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$165.1M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.22 | 3.27%
|
| Avg Daily Range (30 D): |
$0.02 | 4.12%
|
| Avg Daily Range (90 D): |
$0.03 | 4.57%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.19M |
| Avg Daily Volume (30 D): |
5.53M |
| Avg Daily Volume (90 D): |
4.77M |
| Trade Size |
| Avg Trade Size (Sh.): |
217 |
| Avg Trade Size (Sh.) (30 D): |
687 |
| Avg Trade Size (Sh.) (90 D): |
652 |
| Institutional Trades |
| Total Inst.Trades: |
2,786 |
| Avg Inst. Trade: |
$1.51M |
| Avg Inst. Trade (30 D): |
$3.28M |
| Avg Inst. Trade (90 D): |
$1.8M |
| Avg Inst. Trade Volume: |
.18M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.72M |
| Avg Closing Trade (30 D): |
$4.81M |
| Avg Closing Trade (90 D): |
$4.81M |
| Avg Closing Volume: |
211.8K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$-.28
|
$-.08
|
$-.14
|
|
Diluted EPS
|
$-.29
|
$-.08
|
$-.14
|
|
Revenue
|
$ 81.71M
|
$ 18.31M
|
$ 6.44M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -63.31M
|
$ -19.99M
|
$ -30.6M
|
|
Operating Income / Loss
|
$ -62.84M
|
$ -17.86M
|
$ -29.63M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 12.06M
|
$ -2.3M
|
$ -1.28M
|
|
PE Ratio
|
|
|
|
|
|
|
